Sadhak Sengupta

Title: Sadhak Sengupta: Innovator in Cancer Treatment

Introduction

Sadhak Sengupta is a notable inventor based in Sharon, MA (US). He has made significant contributions to the field of cancer therapy through his innovative research and patented methods. His work focuses on enhancing the efficacy of immune cells in targeting cancer cells.

Latest Patents

Sadhak Sengupta holds a patent for "Methods and compositions for treating cancer." This patent describes compositions and methods that involve immune cells expressing both a chimeric antigen receptor that binds to the IL13 receptor α-2 (IL13Rα2) and an O-methylguanine DNA methyltransferase (MGMT) protein. The viral particles containing an IL13 chimeric antigen receptor (IL13CAR) or its variants, along with an MGMT protein or its variants, are utilized to transfect immune cells such as T cells. This transfection imparts both IL13Rα2-targeting activity and resistance to the chemotherapeutic agent temozolomide (TMZ). The methods and compositions outlined in his patent are particularly useful for treating high-grade malignant glioma.

Career Highlights

Sadhak Sengupta is currently associated with Roger Williams Hospital, where he continues to advance his research in cancer treatment. His innovative approach has the potential to significantly improve therapeutic outcomes for patients suffering from aggressive forms of cancer.

Collaborations

Sadhak has collaborated with esteemed colleagues such as Prakash Sampath and Richard P Junghans. Their combined expertise contributes to the ongoing development of effective cancer therapies.

Conclusion

Sadhak Sengupta's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His patented methods represent a promising advancement in the fight against cancer, showcasing the importance of research and collaboration in medical science.